Claim Amendments

1) (Amended) A pharmaceutical composition comprising one or more anticholinergics (1) combined with one or more dopamine agonists (2), each optionally in the form of the enantiomers, mixtures of the enantiomers or in the form of the racemates thereof, and each optionally in the form of the solvates or hydrates thereof, and each optionally together with one or more pharmaceutically acceptable excipients, and wherein anticholinergics (1) are selected from tiotropium salts and oxitropium salts .

Claims 2-4 (Cancelled)

5) (Original) A pharmaceutical composition according to claim 1, characterised in that 1 is present in the form of a chloride, bromide, iodide, methanesulphonate or paratoluene sulphonate salt.

6) (Original) A pharmaceutical composition according to claim 5, characterised in that 1 is present in the form of a bromide salt.

7) (Amended) A pharmaceutical composition according to claim 1, characterised in that 1 is selected from tiotropium bromide and oxitropium bromide.

8) (Original) A pharmaceutical composition according to claim 1, characterised in that 2 is selected from among bromocriptin, cabergolin, alpha-dihydroergocryptin, lisuride, pergolide, pramipexol, roxindol, ropinirol, terguride, talipexol and viozan.

9) (Original) A pharmaceutical composition according to claim 1, characterised in that 2 is selected from pramipexol, talipexol and viozan.

Claims 10-11 (Withdrawn)

12) (Original): A pharmaceutical composition according to claim 1, characterised in that the weight ratios of 1 to 2 are in the range from 1:300 to 50:1.

13) (Original) A pharmaceutical composition according to claim 1, characterised in that the weight ratios of 1 to 2 are in the range from 1:250 to 40:1.

14) (Original) A pharmaceutical composition according to claim 1, characterised in that a single administrative form of the composition contains a dose of the active substance combination of 1 and 2 of 0.01 to 10000µg.

15) (Amended) A pharmaceutical composition according to claim 1, further characterised in that it is a single administrative form which contains a dose of the active substance combination of 1 and 2 of 0.1 to 2000µg.

16) (Original) A pharmaceutical composition according to claim 1, characterised in that it is in the form of a formulation suitable for inhalation.

17) (Original) A pharmaceutical composition according to claim 16, characterised in that it is a formulation selected from among inhalable powders, propellant-containing inhalable aerosols and propellant-free inhalable solutions or suspensions.

18) (Original) A pharmaceutical composition according to claim 17, characterised in that it is an inhalable powder which comprises 1 and 2 in admixture with suitable physiologically acceptable excipients selected from among monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, or mixtures of these excipients with one another.

19) (Original) An inhalable powder according to claim 18, characterised in that the excipients have a maximum average particle size of up to 250µm.

20) (Original) An inhalable powder according to claim 18, characterised in that the excipients have a maximum average particle size of between 10 and 150µm.

21) (Original): A capsule containing an inhalable powder according to claim 18.

22) (Original) A pharmaceutical composition according to claim 17, characterised in that it is an inhalable powder which contains only the active substances 1 and 2 as its ingredients.

Claims 23-44 (Withdrawn)

45) (Original): An inhaler comprising a capsule according to claim 21.

Claims 46-47 (Withdrawn)

48) (Amended): A method of treating inflammatory or obstructive diseases of the respiratory tract, or cystic fibrosis, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a pharmaceutical composition (1) comprising one or more anticholinergics selected from tiotropium salts and oxitropium salts combined with a composition (2) comprising one or more dopamine agonists, each optionally in the form of the enantiomers, mixtures of the enantiomers or in the form of the racemates thereof, and each optionally in the form of the solvates or hydrates thereof, and each optionally together with one or more pharmaceutically acceptable excipients.

49) (Previously Presented) The method according to claim 48, wherein compositions 1 and 2 are administered in a single active formulation.

50) (Previously Presented) The method according to claim 48, wherein compositions 1 and 2 are administered successively in separate formulations.